Datwyler is investing in further expanding its production capacity for high-quality elastomer components for injectable drug delivery systems.
The company is planning to spend more than $102 million USD on building a new plant in Delaware, with construction work likely to get under way before the end of 2016. Production is scheduled to start in the first half of 2018. Once it is fully up and running, Datwyler’s new, highly automated plant in the U.S. will provide jobs for around 120 employees.
Strengthening Datwyler’s position in the key U.S. pharmaceutical market
Datwyler, which has been operating its own plant in the U.S. since 1981, is a supplier to America’s leading healthcare and pharmaceutical providers. With its new production site in Delaware, the company will be able to significantly boost its position in the world’s largest pharmaceutical market.
The new plant is to be designed, built and run in accordance with Datwyler’s latest “FirstLine” standards. This will make it possible to provide customers in the three key business regions of the U.S., Europe and Asia with locally produced first-line components in future.
“FirstLine” standards for high-quality elastomer components
The “FirstLine” standards comprise a manufacturing concept for high-quality elastomer components based on ultra-modern clean room technology, automated production cells, fully automated camera inspection and a unique washing process. This innovative approach to manufacturing exceeds the most stringent quality standards of the European and U.S. regulatory authorities and is certified to ISO 15378.